Breast Cancer: NSABP B-46 (Iowa Cancer Specialists)

NSABP B-46 (I): A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Objective

The main purpose of this study is to learn if adding a drug called bevacizumab to treatment with two chemotherapy drugs for early stage HER2-negative breast cancer will prevent breast cancer from returning.

Bevacizumab is considered investigational because it is still being researched and has not received approval from the U.S. Food and Drug Administration (FDA) for use in treating early stage breast cancer. Bevacizumab is called a targeted therapy because it works by blocking a protein called vascular endothelial growth factor (VEGF) that helps new blood vessels form. Without new blood vessels, the growth of the tumor is slowed.

Two of the chemotherapy drugs used in this study are docetaxel and cyclophosphamide. These drugs are used in standard combinations of chemotherapy for breast cancer.



Principal Investigator(s)
George Kovach

Clinical Trial Categories

  • Cancer
  • Breast Cancer
Sponsor(s)
National Surgical Adjuvant Breast and Bowel Project
Contact
Kim Turner, R.N. at 563-421-1908
or turnerk@genesishealth.com

Location

  • Cancer Care Institute
    1351 West Central Park
    Pavilion 1, 1st Floor
    Davenport, IA 52804
    Main: 563-421-1900
    Alternate: 800-446-6088
    Fax: 563-421-1938

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email